Betahistine in the treatment of Ménière’s disease

Michel Lacour¹, Paul H van de Heyning², Miroslav Novotny³, Brahim Tighilet¹

¹UMR 6149 Université de Provence/CNRS “Neurobiologie Intégrative et Adaptative”, Marseille Cedex 3, France; ²University Department of Otorhinolaryngology. Antwerp University Hopsital, Antwerp, Belgium; ³ENT Clinic, Faculty Hospital, Brno, Czech Republic

Abstract: Ménière’s disease and related disease of the vestibular system are common and debilitating. Current therapy is multi-modal and includes drug therapy and lifestyle adaptations. Unfortunately many of the drugs used in treatment (particularly those used to control nausea) are sedative and hamper the process of vestibular compensation. Although betahistine (Serc^®, BetaSerc^®; Solvay Pharmaceuticals) is the mainstay of drug treatment in these illnesses, its efficacy has not, until recently, been evaluated to modern standards. Betahistine is an analog of histamine with weak agonist properties at histamine H1 receptors and more potent anatgonistic effects at histamine H3 receptors. Growing evidence suggests that the mechanism of action of betahistine lies in the central nervous system and in particularly in the neuronal systems involved in the recovery from process after vestibular loss. The histaminergic neurones of the tuberomamillary and vestibular nuclei are implicated. In recent years the clinical efficacy of betahistine has been demonstrated in double-blind, randomized, placebo, and active controlled studies in adequate numbers of patients. Although the results of comparative studies between betahistine and other drugs (flunarizine, cinnarizine, and cinnarizine + dimenhydrate) are equivocal, the efficacy of betahistine is now clear.

Keywords: Ménière’s disease, vestibular disorders, betahistine